Cardinal Health, Inc. vs McKesson Corporation: Strategic Comparison

This in-depth comparison examines Cardinal Health, Inc. and McKesson Corporation across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Cardinal Health, Inc. on its own, evaluating McKesson Corporation, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Cardinal Health, Inc. and McKesson Corporation is widest.

On the headline numbers, Cardinal Health, Inc. reports annual revenue of $254.2B against $403.4B for McKesson Corporation, while their respective market capitalizations stand at $56.0B and N/A. Cardinal Health, Inc. is headquartered in United States and McKesson Corporation operates from United States, and those different home markets shape how each company competes.

Cardinal Health, Inc.: Cardinal Health is a very large, silent leader of the American healthcare system. Based in Ohio, they do not invent drugs or treat patients. Instead, they are one of the 'Big Three' large pharmaceutical distributors (along with McKesson and Cencora). If a patient picks up a prescription at a local pharmacy, or a surgeon uses a scalpel in a hospital, there is a large probability that Cardinal Health delivered it there. They operate the highly complex, highly regulated supply chain that physically moves billions of pills and medical devices from manufacturers to patients.

McKesson Corporation: McKesson is best understood as healthcare infrastructure. It moves medicines through a regulated network and supports providers and manufacturers with specialty distribution, oncology services, patient-access programs, technology, and medical supplies. The strategic shift is toward higher-growth oncology, multispecialty, and biopharma services while simplifying the portfolio through the European exit and planned Medical-Surgical separation.

Cardinal Health, Inc. and McKesson Corporation pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Cardinal Health, Inc. and McKesson Corporation.

Cardinal Health, Inc. business model: The business model is large, high-volume logistics divided into two segments: Pharmaceutical and Medical. In the Pharma segment, they buy billions of dollars of drugs from manufacturers (like Pfizer) and distribute them daily to tens of thousands of pharmacies and hospitals, taking a tiny markup. In the Medical segment, they actually manufacture and distribute low-cost, high-volume medical supplies (like surgical gloves, gowns, and syringes), acting as the large central supply closet for the entire American hospital system.

McKesson Corporation business model: McKesson makes money primarily by purchasing and distributing pharmaceuticals and medical products to pharmacies, hospitals, health systems, and other providers. Distribution is a high-volume, thin-margin business, so purchasing terms, logistics efficiency, order accuracy, customer contracts, and working-capital management drive results. The company also earns service revenue through oncology and multispecialty provider platforms, biopharma services, prescription access and affordability tools, third-party logistics, and medical-surgical distribution.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Cardinal Health, Inc. stack up against those of McKesson Corporation.

Cardinal Health, Inc. competitive advantage: Cardinal Health's absolute competitive advantage is its large, unreplicable physical scale and deep regulatory entrenchment. Moving highly regulated, temperature-sensitive narcotics and biologics across the country overnight requires a large network of specialized distribution centers and specialized security protocols that take decades and billions of dollars to build. The barrier to entry is so highly high that Cardinal Health operates in a highly insulated oligopoly; a new startup cannot simply disrupt the physical distribution of controlled substances.

McKesson Corporation competitive advantage: McKesson's advantage is the combination of distribution scale, regulated logistics, supplier and customer relationships, specialty capabilities, and nationwide infrastructure. Those assets are expensive and difficult to replicate, but large customers retain negotiating power and the core distribution model remains sensitive to small changes in pricing, product mix, and costs.

Future prospects matter as much as current results. The growth strategies below explain how Cardinal Health, Inc. and McKesson Corporation each plan to expand from here.

Cardinal Health, Inc. growth strategy: Cardinal Health's growth plan rests on three levers. First, specialty pharmaceuticals and physician practice platforms: it bought a 71% stake in GI Alliance for about $2.8 billion (announced November 2024) and funded The Specialty Alliance's roughly $1.9 billion acquisition of urology MSO Solaris Health (completed November 2025). Second, the Other segment: Nuclear and Precision Health Solutions (radiopharmaceuticals and theranostics), at-Home Solutions (expanded with ADSG in 2025, Strive Medical, and the announced AdaptHealth diabetes business), and OptiFreight Logistics, which together grew revenue 26% to $6.8 billion in fiscal 2026. Third, improving GMPD profitability through its Cardinal Health brand products and cost actions.

McKesson Corporation growth strategy: McKesson is concentrating capital on oncology, multispecialty care, and biopharma services, where provider relationships and specialty capabilities can grow faster than traditional wholesale distribution. It is also expanding prescription access and affordability services, completing its exit from Europe, and pursuing a separation of Medical-Surgical Solutions. The objective is a more focused portfolio with better profit growth while preserving the reliability and cash generation of North American pharmaceutical distribution.

A closer look at the financial trajectory of Cardinal Health, Inc. and McKesson Corporation rounds out the comparison.

Cardinal Health, Inc.: Cardinal Health combines very large revenue with thin margins. Fiscal 2026 revenue was $254.2 billion, up 14% from $222.6 billion in fiscal 2025, driven by brand and specialty drug volume from existing customers. GAAP operating earnings were $2.6 billion, GAAP diluted EPS was $7.23, and net earnings attributable to Cardinal Health were about $1.7 billion. Non-GAAP diluted EPS rose 37% to $11.26 ($10.95 excluding the IEEPA tariff refund). Operating cash flow was $5.2 billion and adjusted free cash flow was $5.0 billion. The company repurchased $1.4 billion of stock in fiscal 2026 and the board added $5.0 billion to the buyback authorization in August 2026. Fourth-quarter fiscal 2026 revenue was $63.7 billion, up 6%.

McKesson Corporation: McKesson reported fiscal 2026 revenue of $403.4 billion, up 12%, operating cash flow of $6.2 billion, and free cash flow of $5.4 billion. North American Pharmaceutical produced $336.7 billion of revenue; Oncology & Multispecialty produced $48.4 billion; Prescription Technology Solutions produced $5.8 billion; and Medical-Surgical Solutions produced $11.5 billion. Revenue should be read alongside segment profit and cash flow because distribution and retail represented about 98% of consolidated revenue but operate on thin margins.